How malaria affects the immune response to the Ebola vaccine
Official title: Evaluating the impact of malaria on immunogenicity of the Ebola virus vaccine
Funded at University of Iowa · NIH-10996333 · Data updated 2026-11-12
This study looks at how malaria might affect how well the Ebola vaccine works, especially in places where both diseases are common, to help improve vaccination strategies and protect people better during outbreaks.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $41,385 |
| NIH project number | 1F30AI181340-01A1 |
| Project ID | NIH-10996333 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living in Central and West Africa who are at risk of both malaria and Ebola virus infection.
✕Less likely to help
Patients who do not reside in malaria-endemic regions or who have already been vaccinated against Ebola may not benefit from this research.
What this research studies
This research investigates how malaria infections impact the effectiveness of the Ebola virus vaccine, particularly in regions where both diseases are prevalent. By studying the immune responses in a controlled mouse model, the research aims to understand the mechanisms by which malaria may hinder the body's ability to respond to the Ebola vaccine. The findings could provide insights into improving vaccination strategies in areas heavily affected by both malaria and Ebola, ultimately enhancing public health responses during outbreaks.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccination strategies against Ebola in malaria-endemic regions, potentially saving lives during outbreaks.
How similar studies have gone: Previous research has indicated that malaria can interfere with vaccine efficacy, suggesting that this approach may yield valuable insights into vaccine responses.
Where this research is happening
-
University of Iowa
Iowa City, United States Active
Researchers
- Principal investigator: Elliff, Jonah — University of Iowa
- Study coordinator: Elliff, Jonah
Related research
Other NIH-funded projects on the same topics.
-
Digital malaria surveillance in Ethiopia to improve outbreak detection
A collaboration to add a malaria-specific digital module to an existing surveillance system in Africa to help detect and respond to outbreaks faster.
-
Cross-sector partnership uses digital malaria surveillance in Ethiopia
A US-based team will adapt and test a digital malaria surveillance module in SORMAS to help detect and respond to malaria outbreaks in Ethiopia.
-
Malaria control project in Western Kenya to reduce illness and deaths
A large, multi-year effort in western Kenya will help track malaria spread and test ways to prevent transmission so fewer people get sick or die.
-
Optimizing tafenoquine dose to prevent relapse of vivax malaria in Asia
A study tests the best tafenoquine dose to prevent P. vivax malaria relapse in people in East Asia and Oceania.
-
Optimizing tafenoquine dose to prevent P. vivax malaria relapses in Asia
A study to find the best single-dose tafenoquine amount to prevent relapse of P. vivax malaria in people in East Asia and Oceania.
-
Severe malaria and brain risk in children
This grant studies how severe malaria in young children can affect brain development and long-term thinking and behavior, with a focus on kids in Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.